Richard Nieman - 11 Jul 2022 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role
Chief Medical Officer
Signature
/s/ Jason Cavalier, Attorney-in-Fact for Richard Nieman
Issuer symbol
LYRA
Transactions as of
11 Jul 2022
Net transactions value
$0
Form type
4
Filing time
12 Jul 2022, 16:10:12 UTC
Next filing
02 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYRA Stock Option Award $0 +230,000 $0.000000 230,000 11 Jul 2022 Common Stock 230,000 $6.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests and becomes exercisable as to 25% of the underlying shares on July 11, 2023 and in 36 substantially equal monthly installments thereafter.